Vistagen Therapeutics (VTGN) Net Cash Flow (2010 - 2026)
Vistagen Therapeutics (VTGN) posted Net Cash Flow of -$16.6 million for Q1 2026, down 7.82% sequentially from -$15.4 million in Q4 2025, and down 118.64% YoY from $88.9 million in Q1 2025.
Vistagen Therapeutics (VTGN) Net Cash Flow (2010 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Net Cash Flow for 17 years, with the latest figure at -$16.6 million in Q1 2026.
- Quarterly Net Cash Flow fell 118.64% year-over-year to -$16.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.3 million (up 30.23% YoY) and the FY2026 annual result came in at -$36.3 million, up 30.23% from the prior year.
- Net Cash Flow eased to -$16.6 million in Q1 2026 per VTGN's latest filing, from -$15.4 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $89.0 million in Q4 2023 and troughed at -$18.7 million in Q3 2024.
- A 5-year average of -$3.1 million and a median of -$10.2 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Net Cash Flow slumped 1172.89% in 2022, then surged 967.83% in 2023.
- Over 5 years, Net Cash Flow stood at -$10.2 million in 2022, then soared by 967.83% to $89.0 million in 2023, then tumbled by 110.71% to -$9.5 million in 2024, then sank by 61.36% to -$15.4 million in 2025, then slipped by 7.82% to -$16.6 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$16.6 million, -$15.4 million, and $13.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 225.59 Mn |
| 10 | Vistagen Therapeutics | 10.44 Mn | 10.44 Mn | - | -13.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.58 Mn |
| Mar 31, 2026 | -16.58 Mn |
| Dec 31, 2025 | -15.38 Mn |
| Dec 31, 2025 | -15.38 Mn |
| Sep 30, 2025 | 13.76 Mn |
| Sep 30, 2025 | 13.76 Mn |
| Jun 30, 2025 | -18.10 Mn |
| Jun 30, 2025 | -18.10 Mn |
| Mar 31, 2025 | -7.58 Mn |
| Mar 31, 2025 | -7.58 Mn |
| Dec 31, 2024 | -9.53 Mn |
| Dec 31, 2024 | -9.53 Mn |
| Sep 30, 2024 | -18.67 Mn |
| Sep 30, 2024 | -18.67 Mn |
| Jun 30, 2024 | -16.25 Mn |
| Jun 30, 2024 | -16.25 Mn |
| Mar 31, 2024 | -7.39 Mn |
| Mar 31, 2024 | -7.39 Mn |
| Dec 31, 2023 | 88.95 Mn |
| Dec 31, 2023 | 88.95 Mn |